Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

NCT07454837 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis D

Interventions

DRUG: Brelovitug (BJT-778)
DRUG: Bulevirtide

Sponsor

Mirum Pharmaceuticals, Inc.